

Ocular Hypertension - Pipeline Insight, 2021

<https://marketpublishers.com/r/OB4630EBB447EN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: OB4630EBB447EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Ocular Hypertension - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Ocular Hypertension Understanding

Ocular Hypertension: Overview

Ocular hypertension is elevated intraocular pressure (IOP) without any evidence of glaucomatous optic neuropathy. It is not a disease; however, increased eye pressure is the most important risk factor in the development of open angle glaucoma. Ocular hypertension can be categorized similarly to glaucoma with various possible mechanisms of etiology associated with an open or closed (or narrow) angle and associated primary or secondary causes. Ocular hypertension has no noticeable signs or symptoms. If the pressure is too high there may be pain on eye movement or touch. Diagnosis is usually done by a doctor of optometry who will measure your eye pressure and compare it to normal.

'Ocular Hypertension - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Hypertension.

Ocular Hypertension Emerging Drugs Chapters

This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ocular Hypertension Emerging Drugs

NCX 470: Nicox

NCX 470 is a new chemical entity formulated as an ophthalmic solution of this novel, second generation nitric oxide (NO)-donating prostaglandin analog in development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. NCX 470 is designed to release both bimatoprost and NO following instillation into the eye. Currently, the drug is in phase 3 of development for the treatment of Ocular hypertension.

AGN 193408: AbbVie

AGN-190584 is an investigational optimized formulation of pilocarpine, a cholinergic muscarinic receptor agonist, which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle and is being investigated for the treatment of presbyopia as a topical, once-daily drop delivered by a proprietary vehicle. The proposed mechanism of action of AGN-190584 is through contraction of the iris sphincter muscle, constricting the pupil to enhance the depth of focus and improve near and intermediate visual acuity while maintaining some pupillary response to light. AGN-190584 also contracts the ciliary muscle, facilitating accommodation. The drug is currently in phase I/II of clinical trials for the treatment of Ocular hypertension.

Sepetaprost DE-126: Santen Pharmaceutical

A prostaglandin analogue eye drop drug product with a novel mode of action that is a dual agonist for both FP and EP3 receptors for the treatment of glaucoma and ocular hypertension. Started an additional Phase 2 in December 2020 in the U.S. Phase 2b completed in Japan.

Further product details are provided in the report.....

Ocular Hypertension: Therapeutic Assessment

This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ocular Hypertension

There are approx. 10+ key companies which are developing the therapies for Ocular Hypertension. The companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Nicox.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical

development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ocular Hypertension: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.

Ocular Hypertension Report Insights

Ocular Hypertension Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Ocular Hypertension Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Ocular Hypertension drugs?

How many Ocular Hypertension drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Hypertension?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Ocular Hypertension and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Nicox

Santen Pharmaceutical

AbbVie

MediPrint Ophthalmics

Whitecap Biosciences

Ocular Therapeutix

Sylentis

Chong Kun Dang Pharmaceutical

Aerpio Pharmaceuticals

Key Products

NCX 470

Sepetaprost DE-126

AGN 193408

LL-BMT1

WB007

Travoprost ophthalmic

SYL040012

CKD-351

Razuprotafib

Contents

Introduction

Executive Summary

Ocular Hypertension: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Ocular Hypertension – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Ocular Hypertension companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Ocular Hypertension Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

NCX 470: Nicox

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Sevetaprost DE-126: Santen Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Ocular Hypertension Key Companies

Ocular Hypertension Key Products

Ocular Hypertension- Unmet Needs

Ocular Hypertension- Market Drivers and Barriers

Ocular Hypertension- Future Perspectives and Conclusion

Ocular Hypertension Analyst Views

Ocular Hypertension Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Ocular Hypertension

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Ocular Hypertension
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Ocular Hypertension - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/OB4630EBB447EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OB4630EBB447EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970